A few different elements can make a stock a no-brainer buy. The company could be the leader in its market, or well diversified across various markets.
In the most recent trading session, Intuitive Surgical, Inc. (ISRG) closed at $538.83, indicating a +0.34% shift from the previous trading day.
Intuitive Surgical, Inc. (ISRG) closed the most recent trading day at $523.91, moving -0.49% from the previous trading session.
Recently, Zacks.com users have been paying close attention to Intuitive Surgical (ISRG). This makes it worthwhile to examine what the stock has in store.
What's the hottest S&P 500 stock of 2024? Palantir Technologies (PLTR -0.42%) is the hands-down winner.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen are included in this Analyst Blog.
Here, we discuss five medical device stocks, namely ISRG, GMED, GKOS, VCYT and INGN, which gained in 2024 despite ongoing challenges and provide an attractive investment opportunity for 2025.
Recently, Zacks.com users have been paying close attention to Intuitive Surgical (ISRG). This makes it worthwhile to examine what the stock has in store.
Intuitive Surgical has maintained an uptrend so far this year on the back of robust da Vinci portfolio performance. The has stock also gained during the past month.
Analysis included 230 studies—a mix of randomized, prospective, and database research SUNNYVALE, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:ISRG) The peer-reviewed Annals of Surgery published
In the latest trading session, Intuitive Surgical, Inc. (ISRG) closed at $549.80, marking a +1.49% move from the previous day.
Pointwealth Capital Management CEO & Founder Sandra Cho joins Wealth to discuss her top stock picks across energy, aviation, and healthcare sectors. In the energy sector, Cho highlights Chevron (CVX)
Intuitive Surgical (ISRG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Last year, Morgan Stanley upgraded its outlook for the U.S. MedTech sector to “Attractive,” believing the concerns around GLP-1s were already reflected in stock prices and that fundamentals were s
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE